Sun, Apr 20, 2014, 8:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • markbuti markbuti Dec 6, 2013 6:45 PM Flag

    HIV cure hopes dashed for two US cancer patients

    The latest hopes of curing AIDS were dashed Friday when US researchers said HIV returned in two men who briefly eradicated the virus after bone marrow transplants for cancer.

    Experts described the discovery as a "disappointment," but said it offers important new clues in the hunt for the human immunodeficiency virus's elusive hiding places in the body.

    Only one person is believed to have been cured of HIV. American Timothy Brown, who suffered from leukemia, received a bone marrow transplant from a rare donor who was resistant to HIV, and has shown no sign of the virus for six years.

    "The return of detectable levels of HIV in our patients is disappointing, but scientifically significant," said Timothy Heinrich, a physician-researcher in the Division of Infectious Diseases at Brigham and Women's Hospital in Boston.

    "Through this research we have discovered the HIV reservoir is deeper and more persistent than previously known," he said in a statement sent to AFP.

    Heinrich first shared the news with fellow researchers at an international AIDS conference in Miami, Florida on Thursday.

    Both HIV-positive men received bone marrow transplants as treatment for a kind of blood cancer known as Hodgkin's lymphoma, one in 2008 and the other in 2010.

    About eight months after their operations, HIV was no longer detectable.

    The patients stayed on antiretroviral therapy even after their HIV was undetectable, and eventually decided to cease taking the drugs earlier this year.

    In July, doctors announced early, encouraging results: one patient appeared to still be HIV-free after being off the drugs for seven weeks and the other for 15 weeks.

    But signs of HIV soon returned. They were found in the first patient 12 weeks after stopping therapy, and in the second patient after 32 weeks.

    "Both patients have resumed therapy and are currently doing well," Heinrich said, adding that the patients do not wish to be identified in the media.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • INO to da moon.

    • INO wsa involved or no? who done it?

    • interesting. enter INO

    • He said it was important to share the results with fellow researchers, because they signal "that there may be an important long-lived HIV reservoir outside the blood compartment."

      "We have demonstrated HIV can be reduced to undetectable levels by very sensitive research assays, and the virus persists," he said.

      Prior to the viral rebound, one of the patients had only about 1,000 cells in his body left with traces of HIV, and the other had just 100, according to the Foundation for AIDS Research, amfAR, which funded the study.

      "These two cases are telling us some information that we weren't otherwise going to be able to learn," said Rowena Johnston, director of research at amfAR.

      "As much as it is disappointing for the patients themselves, it is absolutely helping us to learn more about what it is going to take to cure HIV."

      Unlike Brown, these patients' bone marrow transplants did not come from donors that carried a genetic resistance to HIV by lacking a CCR5 receptor, so they were not afforded protection against the virus by that mutation.

      The two men received transplants from donors with the CCR5 receptor, which acts as a gateway allowing HIV to penetrate the cells.

      Researchers had hoped that by continuing to treat the men with antiretroviral drugs during the transplant process and afterward, the medicine might have prevented the donor cells from becoming infected while a new immune system was established.

      Instead, it appears the virus may have been lurking undetected in their bodies, infecting the men as if for the first time once repressive drug therapy was stopped.

      Still, Myron Cohen, an expert on HIV/AIDS at the University of North Carolina at Chapel Hill, said it was too early to draw conclusions.

      "I think we need more information," he told AFP in an email.

      "The reason(s) for suppressed growth of HIV in these patients is still being studied, so recurrence -- if it occurred -- needs to be seen as part of a continuum," he said.

      • 3 Replies to markbuti
      • It was predictable. HIV is known to lurk in nodes in the abdomen. I wonder how hard they searched for suitable donors with natural immunity to HIV, as they did for the German patient, who seems to be cured..

      • He said it was important to share the results with fellow researchers, because they signal "that there may be an important long-lived HIV reservoir outside the blood compartment."

        Hmmm.... seems like a cellular (i.e. T-Cell) based approach to immuno-therapy is in order..... Let me introduce you to Inovio..... There's likely a reason, or multiple reasons, why multiple pharmas are engaged in "Deep Discussions" with Inovio....... 1.) they like Inovio's impressive pre- and clinical study results 2.) they don't like that they (big pharma) can't simply raid INO's IP cookie jar..... Dr. Kim and the leadership team are basically saying... "If you want to play.... you have to pay"...... Great News for shareholders!!!!!!

      • Thank you Mark for your contribution.....It's refreshing to see you and the few others here with a brain post relevant information a midst the mountain of garbage we continue to wade through.

 
INO
2.52-0.15(-5.62%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.